Roivant Sciences Net Income Over Time
| ROIV Stock | USD 21.62 0.40 1.82% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Roivant Sciences Performance and Roivant Sciences Correlation. What growth prospects exist in Biotechnology sector? Can Roivant capture new markets? Factors like these will boost the valuation of Roivant Sciences. Anticipated expansion of Roivant directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each Roivant Sciences valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Quarterly Earnings Growth (0.96) | Earnings Share (0.99) | Revenue Per Share | Quarterly Revenue Growth (0.65) | Return On Assets |
Roivant Sciences's market price often diverges from its book value, the accounting figure shown on Roivant's balance sheet. Smart investors calculate Roivant Sciences' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Since Roivant Sciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Roivant Sciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Roivant Sciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Roivant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Roivant Sciences and related stocks such as Summit Therapeutics PLC, BridgeBio Pharma, and Revolution Medicines Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SMMT | (42 K) | (4.2 M) | (6.7 M) | (10.1 M) | (17.1 M) | (24.3 M) | (21.4 M) | (28.5 M) | 9.9 M | 5 M | (52.7 M) | (86.1 M) | (78.8 M) | (614.9 M) | (221.3 M) | (199.2 M) | (189.2 M) |
| BBIO | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (130.7 M) | (260.4 M) | (448.7 M) | (562.5 M) | (481.2 M) | (643.2 M) | (535.8 M) | (482.2 M) | (506.3 M) |
| RVMD | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (41.8 M) | (47.7 M) | (108.2 M) | (187.1 M) | (248.7 M) | (436.4 M) | (600.1 M) | (540.1 M) | (513.1 M) |
| ASND | 1.2 M | 1.2 M | 1.2 M | 4.1 M | (9.7 M) | (32.9 M) | (68.5 M) | (123.9 M) | (130.1 M) | (218 M) | (419 M) | (383.6 M) | (583.2 M) | (481.4 M) | (378.1 M) | (340.3 M) | (357.3 M) |
| IONS | (4.5 M) | (84.8 M) | (65.5 M) | (60.6 M) | (39 M) | (88.3 M) | (86.6 M) | 346 K | 273.7 M | 294 M | (487 M) | (28.6 M) | (269.7 M) | (366.3 M) | (453.9 M) | (408.5 M) | (388.1 M) |
| EXAS | (3.6 M) | (28.7 M) | (52.4 M) | (46.5 M) | (100 M) | (157.8 M) | (167.2 M) | (114.4 M) | (175.1 M) | (213.1 M) | (823.6 M) | (595.6 M) | (623.5 M) | (204.1 M) | (1 B) | (926 M) | (879.7 M) |
| RNA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (24.7 M) | (44 M) | (117.4 M) | (169.1 M) | (212.2 M) | (322.3 M) | (290.1 M) | (275.6 M) |
| RPRX | (32.5 M) | (32.5 M) | (32.5 M) | (32.5 M) | (32.5 M) | 581.4 M | 565.9 M | 1.2 B | 1.4 B | 2.3 B | 975 M | 619.7 M | 42.8 M | 1.1 B | 859 M | 987.8 M | 968.3 M |
| JAZZ | (24.8 M) | 125 M | 288.6 M | 216.3 M | 58.4 M | 329.5 M | 396.8 M | 487.8 M | 447.1 M | 523.4 M | 238.6 M | (329 M) | (224.1 M) | 414.8 M | 560.1 M | 644.1 M | 676.3 M |
| MRNA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (1.1 M) | (216.2 M) | (255.9 M) | (384.7 M) | (514 M) | (747.1 M) | 12.2 B | 8.4 B | (4.7 B) | (3.6 B) | (4.1 B) | (3.9 B) |
Roivant Sciences and related stocks such as Summit Therapeutics PLC, BridgeBio Pharma, and Revolution Medicines Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Roivant Sciences financial statement analysis. It represents the amount of money remaining after all of Roivant Sciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Roivant Sciences | ROIV |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 50 Broadway, London, |
| Exchange | NASDAQ Exchange |
USD 21.62
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.